TMEM16A Antagonism: Therapeutic Potential with Desensitization of β-Agonist Responsiveness in Asthma
American Journal of Respiratory Cell and Molecular Biology · 2025
DOI: 10.1165/rcmb.2024-0231oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, 2025. Verfasst von Amy Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York. Hauptthemen laut MEDLINE: Anoctamin-1, Asthma, Adrenergic beta-Agonists, Neoplasm Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
The efficacy of β-agonists in asthma is severely limited by β-adrenoceptor desensitization, which results in poorly managed symptoms and refractory bronchoconstriction. Thus, there is a need to identify novel therapeutic pathways and to clarify the relationship between novel therapeutics and functional β-adrenoceptor responsiveness. We have previously demonstrated that acute antagonism of the calcium-activated chloride channel, transmembrane member 16A (TMEM16A), relaxes airway smooth muscle (ASM). We sought to determine the efficacy and role of TMEM16A antagonism in the context of desensitization β-adrenoceptor responsiveness. For these studies, we exposed murine tracheal rings on wire myography and precision-cut lung slices to contractile mediators in the presence or absence of TMEM16A antagonists and β-agonists with or without prior β-adrenoceptor desensitization. Contractile studies were also performed with human tracheal and bronchial ASM. Finally, the ability of TMEM16A antagonism to prevent desensitization of β2-adrenoceptor–induced cAMP synthesis was measured in human ASM cells. From these studies, we demonstrate that acute TMEM16A antagonism is effective in relaxing β-agonist–desensitized ASM in central and peripheral murine ASM and human ASM. Furthermore, we demonstrate that chronic pretreatment with TMEM16A antagonists prevents functional desensitization of β-agonist responsiveness in mouse and human upper airways and prevents desensitization of β-agonist–mediated cAMP production in human ASM cells. Taken together, the present study demonstrates a favorable therapeutic profile of TMEM16A antagonism for ASM relaxation despite functional desensitization of β-agonist responsiveness, which may be a novel therapeutic approach in the face of β-adrenoceptor tachyphylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
ORCID-Profile: Amy Wu
Förderung
- NIGMS NIH HHS
- NIH HHS
- NHLBI NIH HHS
- NIH
Zitieren
APA
Wu, A., Kuforiji, A., Zhang, Y., Xu, D., Perez-Zoghbi, J., Emala, C., & Danielsson, J. (2025). TMEM16A Antagonism: Therapeutic Potential with Desensitization of β-Agonist Responsiveness in Asthma. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2024-0231oc
Vancouver
Wu A, Kuforiji A, Zhang Y, Xu D, Perez-Zoghbi J, Emala C, et al. TMEM16A Antagonism: Therapeutic Potential with Desensitization of β-Agonist Responsiveness in Asthma. American Journal of Respiratory Cell and Molecular Biology. 2025. doi:10.1165/rcmb.2024-0231oc
BibTeX
@article{Wu2025,
author = {Wu, Amy and Kuforiji, Aisha and Zhang, Yi and Xu, Dingbang and Perez-Zoghbi, Jose and Emala, Charles and Danielsson, Jennifer},
title = {TMEM16A Antagonism: Therapeutic Potential with Desensitization of β-Agonist Responsiveness in Asthma},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2025},
doi = {10.1165/rcmb.2024-0231oc}
}
EUVIMED